The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors - Summary - MDSpire

The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors

  • By

  • Melisa Gurbuz

  • Cagla Tekin

  • Melis Ercelik

  • Sevin Avsar Koc

  • Feray Kockar

  • Pınar Eser

  • Mevlut Ozgur Taskapilioglu

  • Gulcin Tezcan

  • Burcu Erbaykent

  • Ahmet Bekar

  • Hasan Kocaeli

  • Mine Ozsen

  • Pınar Karabaglı

  • Hakan Karabaglı

  • Buşra Yaprak Bayrak

  • Volkan Etus

  • Berrin Tunca

  • March 31, 2026

  • 0 min

Share

Objective:

To investigate the clinical significance of lncRNAs, particularly MALAT1, in AT/RT and their interaction with EZH2, emphasizing their potential role in tumor aggressiveness and mesenchymal characteristics.

Key Findings:
  • MALAT1 is significantly dysregulated in AT/RT tissues and interacts with EZH2, suggesting a potential target for therapeutic intervention.
  • Targeting MALAT1 reduces tumor aggressiveness and mesenchymal features in AT/RT models, indicating a shift in treatment strategy.
  • MALAT1-IN-1 shows comparable efficacy to tazemetostat in inhibiting tumor growth, highlighting its potential as an alternative treatment.
Interpretation:

The MALAT1-EZH2 pathway plays a critical role in the aggressiveness of AT/RT, suggesting that targeting this pathway may enhance therapeutic strategies.

Limitations:
  • Small sample size of patient tissues may limit generalizability and the ability to draw broader conclusions.
  • The study primarily focuses on in vitro models, which may not fully replicate in vivo tumor behavior, potentially affecting the applicability of findings.
Conclusion:

Targeting the MALAT1-EZH2 axis presents a promising therapeutic strategy for improving outcomes in pediatric AT/RT, warranting further clinical exploration.

Original Source(s)

The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors

  • by Melisa Gurbuz, Cagla Tekin, Melis Ercelik, Sevin Avsar Koc, Feray Kockar, Pınar Eser, Mevlut Ozgur Taskapilioglu, Gulcin Tezcan, Burcu Erbaykent, Ahmet Bekar, Hasan Kocaeli, Mine Ozsen, Pınar Karabaglı, Hakan Karabaglı, Buşra Yaprak Bayrak, Volkan Etus, Berrin Tunca

  • March 31, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen